A new meta-analysis of over 90,000 patients confirms what clinicians are beginning to see in practice: SGLT2 inhibitors significantly reduce hospitalizations for heart failure and cardiovascular mortality not just in diabetes, but also in heart failure and CKD populations.

Transcript

Speaker 1: You know, when you look at the big health challenges facing us globally, what stands out to you?

Speaker 2: It’s the rise of chronic metabolic diseases like diabetes, high blood pressure, and heart failure. It’s not just about getting these conditions—it’s their impact on people’s lives and longevity. With aging populations and lifestyle changes, this burden is only expected to grow.

Speaker 1: That’s definitely a concern. So what makes finding new management strategies for these conditions so important?

Speaker 2: Any new ways to understand and manage these conditions are crucial, which brings us to the topic today—SGLT2 inhibitors, or sodium-glucose cotransporter-2 inhibitors.

Speaker 1: Right, originally developed for type 2 diabetes. But there’s more to their story now, isn’t there?

Speaker 2: Exactly. Initially, they worked by preventing the kidneys from reabsorbing glucose, lowering blood sugar by increasing glucose excretion in urine. But recent research is revealing broader benefits.

Speaker 1: What kind of benefits are we talking about beyond glucose control?

Speaker 2: There’s strong evidence these drugs help protect the heart and kidneys—not just in people with diabetes, but also in those with heart failure or chronic kidney disease.

Speaker 1: That’s a significant shift in how we view them. What kind of evidence supports this?

Speaker 2: A 2025 systematic review and meta-analysis in Medicino pooled data from 13 randomized controlled trials involving over 90,000 participants. It included studies published between September 2021 and May 2023, giving us a very current picture.

Speaker 1: Let’s start with type 2 diabetes. What did the review show?

Speaker 2: Seven RCTs showed SGLT2 inhibitors significantly reduced the risk of non-fatal myocardial infarction by 12% (HR 0.88, CI 0.78–0.98), heart failure hospitalization by 33% (HR 0.67, CI 0.62–0.74), and cardiac death by 15% (HR 0.85, CI 0.75–0.95).

Speaker 1: Were there any areas where the benefit was less clear?

Speaker 2: Yes, the reduction in non-fatal stroke wasn’t statistically significant (HR 0.95, CI 0.80–1.13).

Speaker 1: What about safety for type 2 diabetes patients?

Speaker 2: Overall adverse events showed a slight, nearly significant reduction (RR 0.98, CI 0.96–1.00). Hypoglycemia wasn’t significantly increased (RR 0.92, CI 0.83–1.02), but there was an 8% increase in urinary tract infections (RR 1.08, CI 1.01–1.16). Importantly, acute kidney injury risk was reduced by 22% (RR 0.78, CI 0.67–0.89).

Speaker 1: How did these drugs perform in people already diagnosed with heart failure?

Speaker 2: Five RCTs showed a 28% reduction in heart failure hospitalization (HR 0.72, CI 0.66–0.77) and a 12% drop in cardiac death (HR 0.88, CI 0.80–0.96). No significant increase in adverse events, hypoglycemia (RR 1.01, CI 0.80–1.29), UTIs (RR 1.13, CI 0.99–1.29), or acute kidney injury (RR 0.94, CI 0.83–1.06) was observed.

Speaker 1: And for patients with chronic kidney disease?

Speaker 2: Four RCTs showed a 35% reduction in heart failure hospitalization (HR 0.65, CI 0.55–0.76), and a 16% reduction in cardiac death (HR 0.84, CI 0.73–0.96). Overall adverse events were reduced by 5% (RR 0.95, CI 0.91–0.99), hypoglycemia risk wasn’t significantly increased (RR 0.94, CI 0.82–1.07), and no significant increase in UTIs (RR 1.06, CI 0.97–1.16). AKI risk was reduced by 19% (RR 0.81, CI 0.69–0.97).

Speaker 1: Did the analysis explore differences based on kidney function?

Speaker 2: Yes, they looked at patients with EGFR above vs. below 45. SGLT2 inhibitors appeared more effective at reducing adverse events in those with better baseline kidney function (EGFR > 45).

Speaker 1: This clearly shows benefits beyond glucose lowering. What are the proposed mechanisms?

Speaker 2: In heart failure, mechanisms may include improved cardiac energy use via ketone metabolism, anti-inflammatory effects, reduced fibrosis, and mild diuretic actions. In CKD, changes in kidney blood flow via tubular-glomerular feedback lower intraglomerular pressure and may reduce inflammation and fibrosis, improving oxygenation and fluid balance.

Speaker 1: What about the earlier concerns over acute kidney injury?

Speaker 2: Initially, dips in EGFR were seen as harmful. But now, larger data suggest these changes reflect protective hemodynamic shifts, not injury. Kidney oxygenation and metabolic changes might also help prevent AKI.

Speaker 1: Let’s talk study limitations.

Speaker 2: Participants were mainly Caucasian or Asian, average age 66, so generalizability could be limited. Trials varied in design, drugs, and dosages, and as a meta-analysis of published data, it’s limited to reported information.

Speaker 1: And the strengths?

Speaker 2: Comprehensive search, robust statistics, large and diverse population, and low bias in included RCTs make this a strong evidence base. They accounted for study differences appropriately.

Speaker 1: Final thoughts—what are the key takeaways?

Speaker 2: SGLT2 inhibitors significantly reduce cardiovascular and kidney risks in T2DM, HF, and CKD. They’re generally safe, with the main caution being a slight UTI increase in T2DM. Overall, they’re emerging as vital tools in managing cardio-renal-metabolic health—not just diabetes.

Transcript has been edited for clarity.